Vaxcell Shares Surge on Announcement of Key Phase 2 Clinical Results [Market Focus]

As of 10:00 a.m. on November 26, shares of the biotech company Vaxcell on the KOSDAQ market were trading at 4,550 won, up by the daily price limit of 29.96% compared to the previous closing price. This surge appears to be due to the announcement of Phase 2 clinical trial results for a key pipeline product.

The previous day, Vaxcell announced that it had completed two years of follow-up observation after dosing in the Phase 2 clinical trial of its natural killer (NK)/T-cell lymphoma treatment, 'VT-EBV-N,' and had received topline (key indicator) results demonstrating statistical significance.

This clinical trial was conducted using randomized and double-blind methods at 13 medical institutions nationwide, including Seoul St. Mary's Hospital. After completing dosing for 48 patients with NK/T-cell lymphoma in September 2023, a two-year observation period was carried out.

According to the analysis results of the final patient cohort received by Vaxcell from the contract research organization, the two-year disease-free survival (DFS), which was the primary efficacy endpoint, was 95.0% in the treatment group and 77.58% in the control group. The difference between the two groups was found to be statistically significant.

In addition, the event rate for recurrence or death in the treatment group was only 4.76% (1 patient), while it was 32% (8 patients) in the control group. The company explained, "VT-EBV-N has shown a meaningful effect in long-term disease suppression for patients with NK/T-cell lymphoma."